

Figure S1. Association between TGFBR1 expression and clinical stage of tumors. (A) Association between TGFBR1 expression and clinical stage in (A) BRCA. (B) Association between TGFBR1 expression and clinical stage in CHOL. (C) Association between TGFBR1 expression and clinical stage in COAD. (D) Association between TGFBR1 expression and clinical stage in ESCA. (E) Association between TGFBR1 expression and clinical stage in HNSC. (F) Association between TGFBR1 expression and clinical stage in KIRC. (G) Association between TGFBR1 expression and clinical stage in LIHC. (H) Association between TGFBR1 expression and clinical stage in LUAD. (I) Association between TGFBR1 expression and clinical stage in LUSC. (J) Association between TGFBR1 expression and clinical stage in MESO. (K) PAAD. (L) Association between TGFBR1 expression and clinical stage in READ. (M) Association between TGFBR1 expression and clinical stage in TGCT. (N) Association between TGFBR1 expression and clinical stage in UVM. (O) Association between TGFBR1 expression and clinical stage in KIRP. TGFBR1, TGF- β receptor 1.




Figure S2. Association between TGFBR1 expression and sex of various tumors. (A) Association between TGFBR1 expression and sex in ACC. (B) Association between TGFBR1 expression and sex in BLCA. (C) Association between TGFBR1 expression and sex in BRCA. (D) Association between TGFBR1 expression and sex in CHOL. (E) Association between TGFBR1 expression and sex in COAD. (F) Association between TGFBR1 expression and sex in DLBC. (G) Association between TGFBR1 expression and sex in ESCA. (H) Association between TGFBR1 expression and sex in GBM. (I) Association between TGFBR1 expression and sex in HNSC. (J) Association between TGFBR1 expression and sex in KICH. (K) KIRC. (L) Association between TGFBR1 expression and sex in KIRP. (M) Association between TGFBR1 expression and sex in LAML. (N) Association between TGFBR1 expression and sex in LGG. (O) Association between TGFBR1 expression and sex in LIHC. (P) Association between TGFBR1 expression and sex in LUAD. (Q) Association between TGFBR1 expression and sex in LUSC. (R) Association between TGFBR1 expression and sex in MESO. (S) Association between TGFBR1 expression and sex in PAAD. (T) Association between TGFBR1 expression and sex in PCPG. (U) Association between TGFBR1 expression and sex in READ. (V) Association between TGFBR1 expression and sex in SARC. (W) Association between TGFBR1 expression and sex in SKCM. (X) Association between TGFBR1 expression and sex in STAD. (Y) Association between TGFBR1 expression and sex in THCA. (Z) Association between TGFBR1 expression and sex in THYM and (a) Association between TGFBR1 expression and sex in UVM. TGFBR1, TGF- β receptor 1.




Figure S3. Association between TGFBR1 expression and grade of various tumors. (A) Association between TGFBR1 expression and tumor grade in CESC. (B) Association between TGFBR1 expression and tumor grade in CHOL. (C) Association between TGFBR1 expression and tumor grade in ESCA. (D) Association between TGFBR1 expression and tumor grade in KIRC. (E) Association between TGFBR1 expression and tumor grade in LIHC. (F) Association between TGFBR1 expression and tumor grade in OV. (G) Association between TGFBR1 expression and tumor grade in PAAD. (H) Association between TGFBR1 expression and tumor grade in UCEC. TGFBR1, TGF- β receptor 1.




Figure S5. Association between TGFBR1 and disease-specific survival in various tumors. (A) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in BLCA. (B) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in BRCA. (C) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in CESC. (D) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in CHOL. (E) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in COAD. (F) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in DLBC. (G) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in ESCA. (H) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in GBM. (I) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in HNSC. (J) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in KICH. (K) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in KIRC. (L) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in KIRP. (M) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in LIHC. (N) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in LUAD. (O) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in LUSC. (P) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in OV. (Q) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in PAAD. (R) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in PCPG. (S) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in PRAD. (T) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in READ. (U) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in SARC. (V) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in SKCM. (W) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in TGCT. (X) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in THCA. (Y) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in THYM. (Z) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in UCEC. (a) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in UCS. (b) Kaplan-Meier analysis of disease-specific survival according to TGFBR1 expression in UVM. TGFBR1, TGF- β receptor 1.




Figure S6. Association between TGFBR1 and disease-free interval in tumors. Kaplan-Meier analysis of disease-free interval according to TGFBR1 expression in (A) BLCA, (B) BRCA, (C) CESC, (D) CHOL, (E) COAD, (F) DLBC, (G) ESCA, (H) KICH, (I) KIRC, (J) KIRP, (K) LGG, (L) LIHC, (M) LUAD, (N) LUSC, (O) MESO, (P) OV, (Q) Kaplan-Meier analysis of disease-free interval according to TGFBR1 expression in PCPG, (R) Kaplan-Meier analysis of disease-free interval according to TGFBR1 expression in PRAD, (S) Kaplan-Meier analysis of disease-free interval according to TGFBR1 expression in READ, (T) Kaplan-Meier analysis of disease-free interval according to TGFBR1 expression in SARC, (U) Kaplan-Meier analysis of disease-free interval according to TGFBR1 expression in STAD, (V) Kaplan-Meier analysis of disease-free interval according to TGFBR1 expression in TGCT, (W) Kaplan-Meier analysis of disease-free interval according to TGFBR1 expression in THCA, (X) UCEC, (Y) Kaplan-Meier analysis of disease-free interval according to TGFBR1 expression in UCS. TGFBR1, TGF- β receptor 1.




Figure S7. Association between TGFBR1 and progression-free interval in various tumors. (A) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in BLCA. (B) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in BRCA. (C) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in CESC. (D) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in CHOL. (E) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in COAD. (F) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in DLBC. (G) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in ESCA. (H) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in HNSC. (I) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in KICH. (J) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in KIRC. (K) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in KIRP. (L) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in LIHC. (M) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in LUAD. (N) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in LUSC. (O) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in MESO. (P) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in OV. (Q) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in PAAD. (R) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in PCPG. (S) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in PRAD. (T) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in READ. (U) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in SARC. (V) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in SKCM. (W) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in STAD. (X) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in TGCT. (Y) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in THCA. (Z) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in THYM. (a) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in UCEC. (b) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in UCS. (c) Kaplan-Meier analysis of progression-free interval according to TGFBR1 expression in UVM. TGFBR1, TGF- β receptor 1.

